Skip to main content

Plaintiffs Ask Merck To Submit Data On Zostavax Vaccine

Plaintiffs Ask Merck To Submit Data On Zostavax Vaccine

Plaintiffs Ask Merck To Submit Data On Zostavax Vaccine

Introduction

According to a motion filed this month, Plaintiff  Executive Committee (PEC) indicated that Merck has refused or delayed to provide adverse reports which include details of injuries, complications, and other negative experiences reported by doctors and patients after receiving the Zostavax vaccine.

The plaintiffs requested the court to force the defendant to turn over the data regarding various Zostavax vaccine problems and to produce their standard operating procedures related to adverse event reports. The opposition response filed by the defendant this week claimed that the plaintiffs’ request was overly broad, arguing that they only had to produce adverse event reports involving the same injuries mentioned in the lawsuits filed till date.

Merck & Co. faces nearly 600 product liability claims, each raising similar allegations that the drugmaker failed to warn about the problems associated with the vaccine which the plaintiffs claim was not sufficient to reduce the reactivation of the dormant virus in some people, resulting in severe and persistent shingles outbreaks, as well as various auto-immune disorders. Zostavax litigation is centralized before U.S. District Judge Harvey Bartle III in the Eastern District of Pennsylvania.

Comments

Restricted HTML

  • Allowed HTML tags: <a href hreflang> <em> <strong> <cite> <blockquote cite> <code> <ul type> <ol start type> <li> <dl> <dt> <dd> <h2 id> <h3 id> <h4 id> <h5 id> <h6 id>
  • Lines and paragraphs break automatically.
  • Web page addresses and email addresses turn into links automatically.

Latest News

NC to Get $150M to Boost Opioid Treatment, Recovery

Categories: Opioids

North Carolina will receive an additional $150 million from Purdue Pharma and the Sackler family as part of a national $7.4 billion settlement related to the opioid

SRI Gets FDA OK for High-Dose Naloxone Trial

Categories: Opioids

SRI has received authorization from the U.S. Food and Drug Administration (FDA) to begin Phase 1 clinical trials of a new, high-dose injectable naloxone formulation.

The approval was granted under an Investigational New Drug (IND)…

Spokane County to Get $5M in New Opioid Settlement

Categories: Opioids

Jurisdictions within Spokane County are set to receive nearly $4.7 million as part of a sweeping $7.4 billion nationwide settlement with Purdue Pharma and its owners, the Sackler family.

The agreement addresses the company’s role in fueling…

✍️ FREE—3000 Pages Medical Record Review Trial!                
No Contract. No Risk—Fully Customized, Free!

Only 10 Firms Accepted—Offer Ends June 30!